DK169766B1 - Fremgangsmåde til fremstilling af polyribonucleotider, der er virksomme ved dannelsen af leucocyter og blodplader - Google Patents
Fremgangsmåde til fremstilling af polyribonucleotider, der er virksomme ved dannelsen af leucocyter og blodplader Download PDFInfo
- Publication number
- DK169766B1 DK169766B1 DK243877A DK243877A DK169766B1 DK 169766 B1 DK169766 B1 DK 169766B1 DK 243877 A DK243877 A DK 243877A DK 243877 A DK243877 A DK 243877A DK 169766 B1 DK169766 B1 DK 169766B1
- Authority
- DK
- Denmark
- Prior art keywords
- ribonuclease
- rna
- rna fragments
- process according
- degradation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 23
- 230000015572 biosynthetic process Effects 0.000 title description 8
- 238000002360 preparation method Methods 0.000 title description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 60
- 239000012634 fragment Substances 0.000 claims description 46
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 241000588724 Escherichia coli Species 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 108010083644 Ribonucleases Proteins 0.000 claims description 16
- 102000006382 Ribonucleases Human genes 0.000 claims description 16
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 11
- 230000015556 catabolic process Effects 0.000 claims description 11
- 238000006731 degradation reaction Methods 0.000 claims description 11
- 239000008346 aqueous phase Substances 0.000 claims description 10
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims description 9
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims description 9
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 8
- 229920002477 rna polymer Polymers 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 210000003705 ribosome Anatomy 0.000 claims description 7
- 238000005194 fractionation Methods 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 4
- 241000221961 Neurospora crassa Species 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 102000002278 Ribosomal Proteins Human genes 0.000 claims 1
- 108010000605 Ribosomal Proteins Proteins 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 28
- 239000000047 product Substances 0.000 description 23
- 239000000243 solution Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 229960000485 methotrexate Drugs 0.000 description 7
- 108020004418 ribosomal RNA Proteins 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000001557 animal structure Anatomy 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- FFLUMYXAPXARJP-JBBNEOJLSA-N 3-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrole-2,5-dione Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CC(=O)NC1=O FFLUMYXAPXARJP-JBBNEOJLSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- FFLUMYXAPXARJP-UHFFFAOYSA-N D-showdomycin Natural products OC1C(O)C(CO)OC1C1=CC(=O)NC1=O FFLUMYXAPXARJP-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010046983 Ribonuclease T1 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 230000003816 axenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000001735 leucopoietic effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000003192 teratological effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7616875A FR2353293A1 (fr) | 1976-06-03 | 1976-06-03 | Polyribonucleotides ayant une activite dans la genese des leucocytes et des plaquettes sanguines |
| FR7616875 | 1976-06-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK243877A DK243877A (da) | 1977-12-04 |
| DK169766B1 true DK169766B1 (da) | 1995-02-20 |
Family
ID=9173980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK243877A DK169766B1 (da) | 1976-06-03 | 1977-06-02 | Fremgangsmåde til fremstilling af polyribonucleotider, der er virksomme ved dannelsen af leucocyter og blodplader |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US4190649A (no) |
| JP (2) | JPS52148613A (no) |
| BE (1) | BE855309A (no) |
| CA (1) | CA1093000A (no) |
| CH (1) | CH620691A5 (no) |
| DE (1) | DE2723451A1 (no) |
| DK (1) | DK169766B1 (no) |
| FR (1) | FR2353293A1 (no) |
| GB (1) | GB1546322A (no) |
| IE (1) | IE45285B1 (no) |
| LU (1) | LU77460A1 (no) |
| NL (1) | NL7705658A (no) |
| NO (1) | NO145540C (no) |
| SE (1) | SE441679B (no) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4558010A (en) * | 1980-04-03 | 1985-12-10 | Abbott Laboratories | Recombinant deoxyribonucleic acid which codes for plasminogen activator and method of making plasminogen activator protein therefrom |
| JPS5927833A (ja) * | 1982-08-06 | 1984-02-14 | Advance Res & Dev Co Ltd | コレステロール乃至トリグリセリド低下剤 |
| JPS59219235A (ja) * | 1983-05-30 | 1984-12-10 | Mitsui Toatsu Chem Inc | 消化性潰瘍用剤 |
| JPS61151128A (ja) * | 1984-12-24 | 1986-07-09 | Advance Res & Dev Co Ltd | コレステロ−ル低下活性ｒｎａ画分 |
| JPS625991A (ja) * | 1985-07-03 | 1987-01-12 | Advance Res & Dev Co Ltd | コレステロ−ル乃至トリグリセリド低下活性ｒｎａ画分 |
| GB2216416B (en) * | 1988-03-11 | 1992-06-24 | Sandoz Ltd | Nucleobase source for the stimulation of the immune system |
| SU1575359A1 (ru) * | 1988-06-14 | 1991-05-15 | Институт Морфологии Человека Амн Ссср | Способ получени рибонуклеотидов |
| PT2097435E (pt) * | 2006-10-27 | 2014-09-17 | Molecular Internat Res Inc | Tratamentos terapêuticos baseados na administração de pequenos fragmentos de arn |
| RU2620069C2 (ru) * | 2014-06-26 | 2017-05-22 | Аоварт Гмбх | Вещество и способ модуляции пролиферации и дифференцировки регуляторных, стволовых и других соматических клеток |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3457254A (en) * | 1965-10-09 | 1969-07-22 | Asahi Chemical Ind | Process for preparing nucleosides |
| BR6801650D0 (pt) * | 1968-08-20 | 1973-03-07 | R Maes | Processo para preparacao de complexos geradores de interferon |
| US3980776A (en) * | 1969-05-26 | 1976-09-14 | Nakao Ishida | Composition containing double stranded RNA from basidiomycetes and method of use |
| BE757653A (fr) * | 1969-10-21 | 1971-04-16 | Ugine Kuhlmann | Nouveaux medicaments derives d'acides nucleiques et procedes pour leur preparation |
| GB1356263A (en) * | 1971-01-14 | 1974-06-12 | Beecham Group Ltd | Modified double-stranded rna |
| BE790953A (fr) * | 1971-11-05 | 1973-05-03 | Beecham Group Ltd | Matiere biologiquement active |
| FR2201879B2 (no) * | 1972-05-19 | 1976-01-23 | Tixier Georges Fr | |
| FR2292481A1 (fr) * | 1974-11-26 | 1976-06-25 | Anvar | Nouveaux polynucleotides, leurs procedes de preparation, et medicaments a base de ces produits |
-
1976
- 1976-06-03 FR FR7616875A patent/FR2353293A1/fr active Granted
-
1977
- 1977-05-23 CH CH629577A patent/CH620691A5/fr not_active IP Right Cessation
- 1977-05-23 NL NL7705658A patent/NL7705658A/xx not_active Application Discontinuation
- 1977-05-24 DE DE19772723451 patent/DE2723451A1/de active Granted
- 1977-05-24 IE IE1060/77A patent/IE45285B1/en not_active IP Right Cessation
- 1977-05-25 US US05/800,435 patent/US4190649A/en not_active Expired - Lifetime
- 1977-05-27 CA CA279,271A patent/CA1093000A/en not_active Expired
- 1977-05-27 NO NO771884A patent/NO145540C/no unknown
- 1977-06-01 LU LU77460A patent/LU77460A1/xx unknown
- 1977-06-01 GB GB23278/77A patent/GB1546322A/en not_active Expired
- 1977-06-02 BE BE2055962A patent/BE855309A/xx not_active IP Right Cessation
- 1977-06-02 SE SE7706425A patent/SE441679B/xx not_active IP Right Cessation
- 1977-06-02 DK DK243877A patent/DK169766B1/da not_active IP Right Cessation
- 1977-06-03 JP JP6498777A patent/JPS52148613A/ja active Granted
-
1979
- 1979-07-03 US US06/054,960 patent/US4335239A/en not_active Expired - Lifetime
-
1987
- 1987-10-28 JP JP62272901A patent/JPS63119495A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6326088B2 (no) | 1988-05-27 |
| JPH027599B2 (no) | 1990-02-19 |
| JPS63119495A (ja) | 1988-05-24 |
| US4335239A (en) | 1982-06-15 |
| BE855309A (fr) | 1977-12-02 |
| US4190649A (en) | 1980-02-26 |
| IE45285L (en) | 1977-12-03 |
| IE45285B1 (en) | 1982-07-28 |
| SE7706425L (sv) | 1977-12-04 |
| FR2353293B1 (no) | 1979-01-12 |
| NL7705658A (nl) | 1977-12-06 |
| NO145540B (no) | 1982-01-04 |
| DE2723451A1 (de) | 1977-12-22 |
| DK243877A (da) | 1977-12-04 |
| GB1546322A (en) | 1979-05-23 |
| JPS52148613A (en) | 1977-12-10 |
| NO771884L (no) | 1977-12-06 |
| CH620691A5 (no) | 1980-12-15 |
| DE2723451C2 (no) | 1989-09-07 |
| FR2353293A1 (fr) | 1977-12-30 |
| NO145540C (no) | 1982-04-14 |
| LU77460A1 (no) | 1978-01-26 |
| CA1093000A (en) | 1981-01-06 |
| SE441679B (sv) | 1985-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU599241B2 (en) | Polysaccharides and antiviral drugs containing the same as active ingredient | |
| Kirby | A new method for the isolation of ribonucleic acids from mammalian tissues | |
| DK169766B1 (da) | Fremgangsmåde til fremstilling af polyribonucleotider, der er virksomme ved dannelsen af leucocyter og blodplader | |
| US4985543A (en) | Lectins and antiretroviral drugs containing the lectins as active ingredient | |
| DK148828B (da) | Fremgangsmaade til fremstilling af polysaccharider med antigen og immunostimulerende virkning | |
| US3821193A (en) | Antiviral complex of rna and polysaccharide | |
| JPH03504970A (ja) | ２′，５′―オリゴアデニレート誘導体の治療的使用 | |
| DE60204967T2 (de) | Verwendung von übersulfatierten polysacchariden als hiv-hemmer | |
| JP2747293B2 (ja) | 細菌感染に対する非特異的防御を刺激するための薬剤 | |
| Xiao et al. | Immunosuppressive activity of polysaccharides from Cordyceps gunnii mycelia in mice in vivo/vitro | |
| US20110070269A1 (en) | Lipopolysaccharide isolated from pyrularia tissue and/or pyrularia-associated bacteria and uses thereof | |
| KR900005170B1 (ko) | 항레트로바이러스 약제 | |
| JPH06702B2 (ja) | 抗アレルギ−剤 | |
| JPH0825892B2 (ja) | 抗ウイルス剤 | |
| US5366725A (en) | Method for the treatment of cancer | |
| JPS63316733A (ja) | 抗ウイルス剤 | |
| JPH0245501A (ja) | 竹節ニンジン多糖およびその用途 | |
| JP2017510288A (ja) | イムノヴィル及びその４成分、イムノヴィルａ，ｂ，ｃ，ｄ，の効用及び有用な製法 | |
| JPH0721003B2 (ja) | 多糖体およびその製造方法 | |
| Kanoh et al. | Pyrogenic principle of the ribonucleic acid from the yeast Candida utilis | |
| JPH0825893B2 (ja) | 抗ウイルス剤 | |
| Stonik | Studies on natural compounds as a road to new drugs | |
| JPS63316727A (ja) | 抗レトロウイルス剤 | |
| TW589320B (en) | Apoptosis inducer | |
| Rajakumar et al. | A Comprehensive Review on the Role of Chemotype Marine Derived-Drug Discovery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PUP | Patent expired |